Online inquiry

IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12586MR)

This product GTTS-WQ12586MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets Felcat NGF gene. The antibody can be applied in Feline osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Felinized
RefSeq XM_004001117.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 100144611
UniProt ID A0A337SBN0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ12586MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3273MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ART621
GTTS-WQ10399MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY2127399
GTTS-WQ11710MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MILR1444A
GTTS-WQ10470MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ14422MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ3542MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAX069
GTTS-WQ1890MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AGEN2034
GTTS-WQ4903MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BYM338
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW